Remuneration

Compensation to the CEO and senior executives

Xspray Pharma must offer levels of compensation and employment conditions on market terms to enable the recruitment and retention of senior executives and key expertise. There are currently no agreements regarding severance pay for senior executives. Compensation to senior executives consists of basic salary, share-related compensation, pension provision and other benefits.

Remuneration report

Klick the links below to download the remuneration report and the auditors statement:

Xspray Pharma Remuneration report 2025
Auditor´s statement under Chapter 8 Section 54 of the Swedish Companies Act (2005:551)

Xspray Pharma Remuneration report 2024
Auditor´s statement under Chapter 8 Section 54 of the Swedish Companies Act (2005:551), Remuneration report 2024

Xspray Pharma Remuneration report 2023
Auditor´s statement under Chapter 8 Section 54 of the Swedish Companies Act (2005:551), Remuneration report 2023

Xspray Pharma Remuneration report 2022
Auditor´s statement under Chapter 8 Section 54 of the Swedish Companies Act (2005:551), Remuneration report 2022

Xspray Pharma Remuneration report 2021
Auditor´s statement under Chapter 8 Section 54 of the Swedish Companies Act (2005:551), Remuneration report 2021

Xspray Pharma Remuneration report 2020
Auditor’s statement under Chapter 8 Section 54 of the Swedish Companies Act (2005:551), Remuneration report 2020

Long term incentive programs

Terms and conditions for the programs can be found in the General Meetings section, link here.

LTIP 2024/2027
The LTIP 2024–2027 warrant program encompasses 129,371 warrants and 266,242 employee stock options that can be exercised during the period from May 24, 2027, through June 11, 2027, at a subscription price of SEK 117.50 per share.
There is a maximum dilution effect of 0,89% on the current number of shares.